Cardiovascular Drugs Practice Questions

Q: Which of the following drugs can cause glucose intolerance?

All of the above. **Explanation:** The correct answer is **D. All of the above**. Several classes of cardiovascular drugs can interfere with glucose metabolism, leading to hyperglycemia or "new-onset diabetes." 1. **Thiazides (e.g., Chlorthalidone, Hydrochlorothiazide):** These are the most common culprits. They cause glucose intolerance primarily through **hypokalemia**. Low extracellular potassium inhibits the release of insulin from pancreatic beta cells (as insulin secretion is a potassium-dependent process). They also decrease peripheral insulin sensitivity. 2. **Propranolol (Non-selective Beta-blockers):** Beta-blockers interfere with carbohydrate metabolism by inhibiting $\beta_2$-mediated insulin release and reducing peripheral glucose uptake. Furthermore, they mask the autonomic warning symptoms of hypoglycemia (like tachycardia and tremors), making them risky for diabetic patients. 3. **Furosemide (Loop Diuretics):** Similar to thiazides, loop diuretics can cause hyperglycemia, though generally to a lesser extent. The mechanism is again linked to hypokalemia-induced inhibition of insulin secretion. **High-Yield Clinical Pearls for NEET-PG:** * **Drug of choice for HTN in Diabetics:** ACE inhibitors or ARBs (they are Reno-protective and metabolic-neutral). * **Metabolic Side Effects of Thiazides:** Remember the mnemonic **"Hyper-GLUC"** (Hyper**G**lycemia, Hyper**L**ipidemia, Hyper**U**ricemia, Hyper**C**alcemia). * **Beta-blocker exception:** Vasodilatory beta-blockers like **Carvedilol** and **Nebivolol** have a neutral or even beneficial effect on glycemic control compared to Propranolol. * **Potassium Link:** Maintaining normal serum potassium levels can often reverse or mitigate diuretic-induced glucose intolerance.

Q: Lovastatin acts by inhibiting which enzyme?

HMGCoA reductase. **Explanation:** **Mechanism of Action (Why Option A is correct):** Lovastatin belongs to the class of drugs known as **Statins**. These are competitive inhibitors of **HMG-CoA reductase** (3-hydroxy-3-methylglutaryl-coenzyme A reductase). This enzyme is the rate-limiting step in the mevalonate pathway of hepatic cholesterol synthesis. By inhibiting this enzyme, statins decrease intracellular cholesterol levels, leading to an up-regulation of LDL receptors on hepatocytes, which increases the clearance of LDL-cholesterol from the blood. **Analysis of Incorrect Options:** * **Option B (HMG-CoA synthetase):** This enzyme acts upstream of HMG-CoA reductase in the cholesterol synthesis pathway (converting Acetyl-CoA to HMG-CoA). It is not the target of any current clinical lipid-lowering drugs. * **Option C (17-Hydroxylase):** This enzyme is involved in the steroidogenesis pathway (adrenal and gonadal hormones). Its inhibition (e.g., by Abiraterone) is used in treating prostate cancer, not hyperlipidemia. * **Option D (Bile-acid synthetase):** This is involved in converting cholesterol into bile acids. Drugs like Bile Acid Sequestrants (e.g., Cholestyramine) bind bile acids in the gut but do not inhibit this enzyme directly. **High-Yield Clinical Pearls for NEET-PG:** * **Pleiotropic Effects:** Statins have anti-inflammatory and plaque-stabilizing effects beyond lipid lowering. * **Timing:** Statins with short half-lives (Lovastatin, Simvastatin) should be taken at **night** because peak cholesterol synthesis occurs during sleep. * **Adverse Effects:** The most important side effects are **myopathy/rhabdomyolysis** (monitored via CPK levels) and **hepatotoxicity** (monitored via LFTs). * **Contraindication:** Statins are strictly **Teratogenic** (Category X).

Q: With respect to ticlopidine, which of the following is true for clopidogrel?

Is less likely to cause neutropenia. Ticlopidine and clopidogrel are both **P2Y12 receptor antagonists** (thienopyridines) that inhibit ADP-induced platelet aggregation. While they share a similar mechanism of action, clopidogrel was developed as a second-generation agent specifically to improve the safety profile. **1. Why Option B is Correct:** The most significant clinical difference between the two is the risk of **hematological toxicity**. Ticlopidine is associated with life-threatening **neutropenia** (approximately 1% of patients) and agranulocytosis, requiring frequent CBC monitoring during the first three months of therapy [1]. Clopidogrel has a significantly lower incidence of neutropenia, making it the preferred clinical choice. **2. Why Incorrect Options are Wrong:** * **Option A:** Neither drug is typically associated with the formation of antiplatelet antibodies (this is more characteristic of Heparin-Induced Thrombocytopenia). * **Option C:** Clopidogrel does not inherently cause more severe bleeding than ticlopidine; their bleeding risks are comparable when used at standard therapeutic doses. * **Option D:** Both drugs are prodrugs that require hepatic activation (via CYP450). While clopidogrel is more potent and has a faster onset of action, the primary reason for its preference in clinical practice is its superior safety profile rather than a vastly "greater" antiplatelet ceiling. **High-Yield Clinical Pearls for NEET-PG:** * **Mechanism:** Irreversible inhibition of P2Y12 ADP receptors, leading to decreased activation of the GPIIb/IIIa complex. * **Toxicity:** Ticlopidine causes neutropenia and **TTP** (Thrombotic Thrombocytopenic Purpura) [1]. Clopidogrel can also cause TTP, but it is much rarer. * **Pharmacogenetics:** Clopidogrel is a prodrug activated by **CYP2C19**. Patients who are "poor metabolizers" of this enzyme (or those taking **Omeprazole**, a CYP2C19 inhibitor) will have reduced antiplatelet efficacy [2].

Q: Which of the following antihypertensives is used in premenstrual syndrome?

Clonidine. **Explanation:** **Clonidine** is a centrally acting **$\alpha_2$-adrenergic agonist**. While primarily used as an antihypertensive, it is effective in managing **Premenstrual Syndrome (PMS)** and menopausal symptoms. The underlying medical concept involves its ability to reduce sympathetic outflow and modulate neuroendocrine fluctuations. Specifically, it helps alleviate vasomotor symptoms (hot flashes), irritability, and certain physical discomforts associated with the luteal phase of the menstrual cycle. **Analysis of Incorrect Options:** * **Hydralazine:** A direct-acting vasodilator used primarily in hypertensive emergencies and pregnancy-induced hypertension (PIH). It has no role in hormonal or symptomatic management of PMS. * **Losartan:** An Angiotensin II Receptor Blocker (ARB). It is used for chronic hypertension and diabetic nephropathy but does not cross the blood-brain barrier effectively or influence the symptoms of PMS. * **Amlodipine:** A Calcium Channel Blocker (CCB) used for hypertension and angina. It acts on peripheral vascular smooth muscle and lacks the central neuromodulatory effects required to treat PMS. **High-Yield Clinical Pearls for NEET-PG:** * **Other uses of Clonidine:** Opioid withdrawal (reduces sympathetic overactivity), ADHD, Tourette syndrome, and prophylaxis of migraine. * **Side Effects:** Sedation, mental depression, and **marked dryness of mouth**. * **Rebound Hypertension:** Sudden withdrawal of clonidine can lead to a hypertensive crisis due to a massive release of stored catecholamines. * **Drug of Choice for PMS:** While clonidine is an option, **SSRIs** (like Fluoxetine) are generally considered the first-line pharmacological treatment for severe PMS/PMDD.

Q: Which of the following statements about hydralazine is NOT true?

It causes dilatation of both arteries and veins.. **Explanation:** Hydralazine is a **direct-acting vasodilator** primarily used in the management of hypertensive emergencies (especially in pregnancy) and chronic heart failure (in combination with nitrates). **1. Why Option B is the correct answer (The False Statement):** Hydralazine is a **selective arterial vasodilator**. It acts directly on the smooth muscles of the arterioles but has **minimal to no effect on the venous system** (veins). Because it does not cause venodilation, it does not significantly decrease preload or cause the peripheral venous pooling that leads to orthostatic hypotension. **2. Analysis of Incorrect Options (True Statements):** * **Option A:** Hydralazine causes **direct relaxation** of vascular smooth muscle, likely by interfering with calcium metabolism and increasing local nitric oxide levels. * **Option C:** Since hydralazine does not affect the venous capacitance vessels, **postural (orthostatic) hypotension is rare**, unlike with alpha-blockers or nitrates. * **Option D:** Arteriolar dilation triggers a **baroreceptor-mediated sympathetic surge**. This leads to reflex tachycardia and an **increase in plasma renin activity**, causing sodium and water retention. This is why it is often co-administered with a beta-blocker and a diuretic. **High-Yield Clinical Pearls for NEET-PG:** * **Drug-Induced Lupus Erythematosus (DILE):** A classic side effect of hydralazine, especially in **slow acetylators**. It is associated with **Anti-Histone Antibodies**. * **Drug of Choice:** It is a preferred parenteral drug for **Hypertension in Pregnancy** (Preeclampsia/Eclampsia). * **Combination Therapy:** When combined with **Isosorbide Dinitrate (BiDil)**, it has been shown to improve mortality in African-American patients with heart failure.

Q: Which of the following drugs is NOT used in the management of chronic heart failure?

Isosorbide dinitrate. **Explanation:** The management of Chronic Heart Failure (CHF) focuses on drugs that provide a **mortality benefit** by inhibiting maladaptive neurohormonal remodeling (the RAAS and sympathetic nervous system). **Why Isosorbide Dinitrate is the correct answer:** While nitrates are potent vasodilators, **Isosorbide dinitrate (ISDN) alone** is typically used for symptomatic relief in acute heart failure or angina. In chronic heart failure, it does not provide a significant survival benefit when used as monotherapy. It is only recommended for chronic management when **combined with Hydralazine** (BiDil), specifically in patients of African-American descent or those intolerant to ACE inhibitors/ARBs [1, 2]. **Analysis of Incorrect Options:** * **Lisinopril (ACE Inhibitor):** These are first-line agents in CHF. they decrease preload and afterload and, most importantly, prevent cardiac remodeling, significantly reducing mortality [1]. * **Spironolactone (Mineralocorticoid Receptor Antagonist):** It blocks the effects of aldosterone. Clinical trials (like RALES) have proven it reduces mortality and hospitalization in patients with NYHA Class II-IV heart failure [1]. * **Losartan (ARB):** Used as an alternative to ACE inhibitors (especially if the patient develops a cough). Like ACE inhibitors, ARBs provide a mortality benefit by blocking the RAAS pathway [1]. **High-Yield Clinical Pearls for NEET-PG:** * **Drugs improving survival in CHF:** ACE inhibitors, ARBs, Beta-blockers (Carvedilol, Metoprolol succinate, Bisoprolol), Spironolactone, and ARNIs (Sacubitril/Valsartan). * **Drugs only for symptomatic relief (No mortality benefit):** Digoxin, Loop diuretics (Furosemide), and Ionotropes (Dopamine/Dobutamine) [1]. * **Hydralazine + ISDN:** The only nitrate combination proven to reduce mortality in specific populations (African-Americans) [1, 2].

Q: Which of the following is a new drug that acts by inhibiting PCSK9?

Alirocumab. **Explanation:** **Alirocumab** is a human monoclonal antibody that acts as a **PCSK9 inhibitor**. **Mechanism of Action:** PCSK9 (Proprotein Convertase Subtilisin/Kexin type 9) is an enzyme that binds to LDL receptors (LDL-R) on the surface of hepatocytes and promotes their degradation. By inhibiting PCSK9, Alirocumab increases the number of available LDL receptors on the liver cell surface. This leads to increased clearance of LDL-cholesterol from the blood, significantly lowering plasma LDL levels. It is primarily used in patients with familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease requiring additional LDL lowering. **Analysis of Incorrect Options:** * **Reslizumab (A):** An interleukin-5 (IL-5) antagonist used as add-on maintenance treatment for severe eosinophilic asthma. * **Brodalumab (B):** An interleukin-17 (IL-17) receptor antagonist used in the treatment of moderate-to-severe plaque psoriasis. * **Ixekizumab (D):** Another IL-17A inhibitor used for plaque psoriasis and psoriatic arthritis. **High-Yield Clinical Pearls for NEET-PG:** * **PCSK9 Inhibitors:** Include **Alirocumab** and **Evolocumab**. They are administered via subcutaneous injection every 2–4 weeks. * **Efficacy:** They can reduce LDL-C by up to 50–70%, even in patients already on maximal statin therapy. * **Inclisiran:** A newer agent (small interfering RNA or siRNA) that also targets PCSK9 synthesis in the liver but has a longer duration of action (dosed every 6 months). * **Adverse Effects:** Generally well-tolerated; most common side effects include injection site reactions and nasopharyngitis.

Question 1

A diabetic patient with autonomic neuropathy presents with dizziness and hypotension upon waking. What is the drug of choice for this condition?

Accepted Answer

Midodrine

Answer

Dopamine / Dobutamine

Answer

Isoproterenol

Answer

Clonidine

Question 2

Which of the following drugs can cause glucose intolerance?

Accepted Answer

All of the above

Answer

Thiazides

Answer

Propranolol

Answer

Furosemide

Question 3

Lovastatin acts by inhibiting which enzyme?

Accepted Answer

HMGCoA reductase

Answer

HMGCoA synthetase

Answer

17-Hydroxylase

Answer

Bile-acid synthetase

Question 4

With respect to ticlopidine, which of the following is true for clopidogrel?

Accepted Answer

Is less likely to cause neutropenia

Answer

Is more likely to cause formation of antiplatelet antibodies

Answer

Is more likely to cause severe bleeding

Answer

Has a greater antiplatelet effect

Question 5

Which of the following antihypertensives is used in premenstrual syndrome?

Accepted Answer

Clonidine

Answer

Hydralazine

Answer

Losartan

Answer

Amlodipine

Question 6

A 59-year-old woman with type II diabetes mellitus and a BMI of 30 experiences an episode of chest pain with exercise. Angiography reveals proximal coronary arterial narrowing with up to 70% stenosis. Which of the following pharmacologic agents ingested in low doses daily is most appropriate for reducing her risk for myocardial infarction?

Accepted Answer

Aspirin

Answer

Acetaminophen

Answer

Ibuprofen

Answer

Paclitaxel

Question 7

Which of the following statements about hydralazine is NOT true?

Accepted Answer

It causes dilatation of both arteries and veins.

Answer

It causes direct relaxation of blood vessels.

Answer

Postural hypotension is not a common problem.

Answer

It increases plasma renin activity.

Question 8

Which of the following drugs is NOT used in the management of chronic heart failure?

Accepted Answer

Isosorbide dinitrate

Answer

Lisinopril

Answer

Spironolactone

Answer

Losartan

Question 9

Which of the following is a new drug that acts by inhibiting PCSK9?

Accepted Answer

Alirocumab

Answer

Reslizumab

Answer

Brodalumab

Answer

Ixekizumab

Question 10

Spironolactone is contraindicated with which of the following drugs?

Accepted Answer

Enalapril

Answer

Atenolol

Answer

Verapamil

Answer

Chlorthiazide

Cardiovascular Drugs — MCQs

Cardiovascular Drugs — MCQs

On this page

Practice by Chapter

Want unlimited practice?